Els Van Nieuwenhuysen, MD, of University Hospitals Leuven in Belgium, reviews phase 1/2 data on ubamatamab, a mucin-16 (MUC16) by CD3 bispecific antibody, in patients with recurrent low-grade serous ovarian cancer, as presented at the 2026 International Gynecologic Cancer Society Annual Global Meeting.